MorphoSys (MOR) Given a €57.00 Price Target at Royal Bank of Canada

Royal Bank of Canada set a €57.00 ($70.37) price target on MorphoSys (ETR:MOR) in a research note released on Wednesday. The brokerage currently has a sell rating on the stock.

Other equities research analysts have also issued research reports about the stock. Commerzbank set a €76.00 ($93.83) price target on shares of MorphoSys and gave the stock a buy rating in a report on Tuesday, October 24th. Berenberg Bank set a €85.00 ($104.94) target price on shares of MorphoSys and gave the stock a buy rating in a report on Thursday, October 19th. Deutsche Bank set a €90.00 ($111.11) target price on shares of MorphoSys and gave the stock a buy rating in a report on Wednesday, November 8th. Oddo Bhf set a €90.00 ($111.11) target price on shares of MorphoSys and gave the stock a buy rating in a report on Wednesday, November 8th. Finally, JPMorgan Chase & Co. set a €85.00 ($104.94) target price on shares of MorphoSys and gave the stock a buy rating in a report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. MorphoSys has an average rating of Hold and an average price target of €79.10 ($97.65).

Shares of MorphoSys (ETR:MOR) opened at €71.60 ($88.40) on Wednesday. The company has a market cap of $2,160.00 and a price-to-earnings ratio of -24.27. MorphoSys has a 1-year low of €48.25 ($59.57) and a 1-year high of €87.35 ($107.84).

COPYRIGHT VIOLATION NOTICE: “MorphoSys (MOR) Given a €57.00 Price Target at Royal Bank of Canada” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/02/15/morphosys-mor-given-a-57-00-price-target-at-royal-bank-of-canada.html.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply